Can a biomarker test unlock better treatment for Right-Sided colon cancer?
NCT ID NCT07094893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 4 trial is for people with advanced colorectal cancer that started on the right side of the colon and has a normal RAS gene. Researchers want to see if adding the targeted drug cetuximab to standard chemotherapy helps shrink tumors more than chemotherapy alone or with bevacizumab. The study will also check if a biomarker test (EREG/AREG) can predict who benefits most. About 280 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab (anti-EGFR drug) combined with chemotherapy (irinotecan, oxaliplatin, 5-FU, capecitabine) and/or bevacizumab
What this could lead to
If successful, this could show that a biomarker test (EREG/AREG) helps identify which patients with right-sided colon cancer benefit from adding cetuximab to standard chemotherapy, potentially improving tumor shrinkage and survival.
What could go wrong
This trial is not yet recruiting and is relatively small (280 participants). The benefit may be limited to a specific biomarker subgroup, and anti-EGFR drugs can cause skin reactions and other side effects. Results may not apply to all colorectal cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••